Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Werewolf Therapeutics (HOWL) Interest Expenses (2023 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Interest Expenses for 3 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Interest Expenses rose 7.8% to $1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.2 million, a 17.57% increase, with the full-year FY2024 number at $4.7 million, up 48.33% from a year prior.
  • Interest Expenses was $1.3 million for Q3 2025 at Werewolf Therapeutics, up from $1.3 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $1.3 million in Q3 2025 to a low of $172000.0 in Q1 2023.
  • A 3-year average of $1.1 million and a median of $1.1 million in 2024 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: skyrocketed 483.14% in 2024, then rose 7.8% in 2025.
  • Werewolf Therapeutics' Interest Expenses stood at $1.0 million in 2023, then grew by 25.45% to $1.3 million in 2024, then increased by 5.84% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Interest Expenses are $1.3 million (Q3 2025), $1.3 million (Q2 2025), and $1.3 million (Q1 2025).